Within a week, preclinical tests of the new coronavirus vaccine developed by Takis, a biotechnology company based on a fragment of virus genetic material, will begin in Italy. They will test the vaccine in animals. She reported on Wednesday the Italian ANSA with the approval of preclinical testing Italian Ministry of Health.

Initial laboratory tests indicate that the vaccine is capable of inducing “A strong immune response,” Takis said. If they will the results of the first tests on animals satisfactory, will start in the autumn with human testing. ANSA specified that the vaccine was developed on the basis of a genetic fragment virus and will be applied using a technology called electroporation when the vaccine is injected into the muscle very briefly an electrical pulse facilitating its entry into the cells.